Page last updated: 2024-11-05

troglitazone and Renal Insufficiency

troglitazone has been researched along with Renal Insufficiency in 1 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ogawa, M1
Hirawa, N1
Tsuchida, T1
Eguchi, N1
Kawabata, Y1
Numabe, A1
Negoro, H1
Hakamada-Taguchi, R1
Seiki, K1
Umemura, S1
Urade, Y1
Uehara, Y1

Other Studies

1 other study available for troglitazone and Renal Insufficiency

ArticleYear
Urinary excretions of lipocalin-type prostaglandin D2 synthase predict the development of proteinuria and renal injury in OLETF rats.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2006, Volume: 21, Issue:4

    Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Hypoglycemic Agents; Immunoenz

2006